SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Apple Turns 50: From Garage Startup to AI Crossroads 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
MINNEAPOLIS, Nov. 22, 2016 -- Lockridge Grindal Nauen P.L.L.P. announces that a class action has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) (NYSE:ALXN) securities between February 10, 2014 through November 9, 2016 (the “Class Period”).
If you are a member of the proposed Class, you may move the Court to serve as a lead plaintiff for the Class on or before January 17, 2017. You do not need to be a lead plaintiff in order to share in any recovery that may be obtained.
The Complaint alleges Alexion made false and/or misleading statements and/or failed to disclose: 1) that the Company employed improper sales practices with respect to its product Soliris; 2) that the Company’s revenues from Soliris sales were unlikely to be sustainable; and 3) that as a result of the above, Alexion’s public statements were materially false and misleading at all relevant times. On November 4, 2016, Alexion cancelled an appearance at the Credit Suisse Healthcare Conference. Following the cancellation, analysts noticed that the Company also failed to file its Quarterly Report on Form 10-Q with the SEC within two days of its earnings announcement on October 27, 2016. On this news, Alexion’s share price fell $8.95, or 6.94%, to close at $120.05 on November 7, 2016. On November 9, 2016, Alexion announced that the Company would not be able to timely file its financial and operating results for the quarter ended September 30, 2016. When this information was disclosed, shares of Alexion declined in value, causing investors harm. On this news, Alexion’s share price fell $0.28, or 0.22%, to close at $126.88 on November 10, 2016. As the market continued to digest the significance of Alexion’s announced investigation, Alexion’s share price fell an additional $13.26, or 10.45%, to close at $113.62 on November 11, 2016.
If you purchased Alexion Pharmaceuticals, Inc. stock during the Class Period, or have any questions concerning this notice or your rights with respect to this matter, please contact:
Gregg M. Fishbein, Esq. ([email protected])
Lockridge Grindal Nauen P.L.L.P.
100 Washington Avenue South, Suite 2200
Minneapolis, MN 55401
(612) 339-6900
